Compound · clinical trials

IMGN632 clinical trials

Also listed in trial records as CD123-targeted ADC

Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 2 trials in our UK, USA, Germany, France, Spain and Italy registers that name IMGN632 as an intervention. Synced 9 Nov 2026

2Current trials

0Recruiting now

1Lead sponsor

6Country registers

Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov registry records · Synced 9 Nov 2026 · Editorial standards

At a glance

IMGN632 is named as an intervention in 2 current clinical trials in our UK, USA, Germany, France, Spain and Italy registers. None are recruiting at the moment. All registered phases are Phase 1/2. The lead sponsor is AbbVie. The most-studied condition is Blastic Plasmacytoid Dendritic Cell Neoplasm.

Patient leaflets for IMGN632

The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.

UK
United Kingdom: Search MHRA Products
Patient information leaflets and SmPCs for UK-licensed products.
US
United States: Search DailyMed
FDA-approved labels, including patient and medication guides.

Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.

Trials by status

Active, closed2100%

Trials by phase

Phase 1/22100%

Clinical trials of IMGN632

2 trials

Study	Phase	Status	Lead sponsor	Registers
Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN NCT03386513 · Blastic Plasmacytoid Dendritic Cell Neoplasm, Myeloproliferative Neoplasm	Phase 1/2	Active, closed	AbbVie	UK, USA, Germany, France, Spain, Italy
IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia NCT04086264 · Acute Myeloid Leukemia	Phase 1/2	Active, closed	AbbVie	UK, USA, Germany, France, Spain, Italy

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

Conditions studied with IMGN632

3 conditions

Blastic Plasmacytoid Dendritic Cell Neoplasm1Myeloproliferative Neoplasm1 Acute Myeloid Leukemia1

By country register

Register	Trials	Recruiting
Clinical trials in UK	2	0
Clinical trials in USA	2	0
Clinical trials in Germany	2	0
Clinical trials in France	2	0
Clinical trials in Spain	2	0
Clinical trials in Italy	2	0

A trial with sites in more than one country appears in each of those registers.

Related compounds

Questions about IMGN632 trials

How many clinical trials are testing IMGN632?

2 current trials in our UK, USA, Germany, France, Spain and Italy registers name IMGN632 (also registered as CD123-targeted ADC) as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.

Are IMGN632 trials recruiting patients?

Not at the moment. None of the 2 trials in our registers is recruiting; they are active but closed to enrolment, not yet open, or enrolling by invitation. Only the study team can confirm whether a patient is eligible.

Who sponsors IMGN632 clinical trials?

The lead sponsor is AbbVie. The number in brackets is how many trials each organisation leads.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how IMGN632 works or whether it is effective, and it is not medical advice.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how IMGN632 works or whether it is effective. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists IMGN632 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.